GSK

News

New RUBY readout buoys GSK’s Jemperli in endometrial cancer

GSK has said that a regimen of PD-1 inhibitor Jemperli with PARP inhibitor Zejula has shown efficacy in the second stage of the RUBY trial, which could open up wider use i

News

Is GSK’s Blenrep heading for a renaissance?

A year after GSK pulled its BCMA-targeting antibody-drug conjugate (ADC) Blenrep from the US market as a later-line therapy for multiple myeloma, there are signs that the

News

Sosei sees $3bn sales potential for GSK's IBD discard

Sosei Heptares has lost GSK as a partner for an inflammatory bowel disease (IBD) drug candidate GSK4381406, but says it will take the programme forward as it has significa

News

GSK says new inhaler will help slash its carbon footprint

GSK has developed a new propellant technology for inhaler devices that drastically reduces their use of greenhouse gases, which perhaps surprisingly account for nearly hal

News

CHMP backs GSK’s momelotinib for myelofibrosis

GSK is on the brink of EU approval for JAK inhibitor momelotinib as a treatment for myelofibrosis patients with anaemia, after the EMA’s human medicines committee issued a

News

GSK grabs early lead in RSV vaccine race with Pfizer

It is still very early days, but GSK’s respiratory syncytial virus (RSV) Arexvy seems to have flown out of the traps more quickly than Pfizer’s rival shot Abrysvo in the f

New RUBY readout buoys GSK’s Jemperli in endometrial cancer

Is GSK’s Blenrep heading for a renaissance?

Sosei sees $3bn sales potential for GSK's IBD discard

GSK says new inhaler will help slash its carbon footprint

CHMP backs GSK’s momelotinib for myelofibrosis

GSK grabs early lead in RSV vaccine race with Pfizer

UK issues £45m funding call for research partnerships

Discover a new era of healthcare panel engagement: Grounded ...

GSK

Editor's Picks